Health care resource utilization in 3L+patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib

Article Oncology

Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update.

Delphine Rea et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Hematology

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Delphine Rea et al.

Summary: Asciminib demonstrated superior efficacy compared to bosutinib in treating patients with CML-CP who are resistant or intolerant to >= 2 prior TKIs, with a favorable safety profile.

BLOOD (2021)

添加到收藏夹

Article Hematology

CML-353: Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial

B Douglas Smith et al.

Clinical Lymphoma Myeloma & Leukemia (2021)

添加到收藏夹

Article Economics

PCN231 Humanistic and Economic Burden in Patients with Chronic Myeloid Leukemia Â– A Review of the Literature

H. Negi et al.

VALUE IN HEALTH (2021)

添加到收藏夹

Article Oncology

Magnitude and Temporal Trend of the Chronic Myeloid Leukemia: On the Basis of the Global Burden of Disease Study 2019

Yuefen Hu et al.

Summary: The study found that while the incidence rate of chronic myeloid leukemia (CML) has decreased globally, the number of new cases is still on the rise. However, there has been a significant reduction in death rate and disability-adjusted life years rate, especially in high-income regions. The primary attributable risk factors for CML globally in 2019 were smoking, high BMI, occupational exposure to benzene, and formaldehyde. Therefore, it is important to prioritize the management of CML patients, especially in elderly and developing regions.

JCO GLOBAL ONCOLOGY (2021)

添加到收藏夹

Article Hematology